Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7259070 | 0.75 | CYP3A4 (0.36) | TDO2 | |
| SCHEMBL9341524 | 0.75 | TDO2 (0.30) | TDO2 | |
| SCHEMBL4850782 | 0.75 | MEN1 (0.31) | GAAMEN1KMT2A | |
| SCHEMBL6308270 | 0.75 | TERT (0.30) | — | |
| SCHEMBL21246679 | 0.73 | KMT2A (0.41) | GAAMEN1KMT2A | |
| SCHEMBL24124151 | 0.71 | TERT (0.37) | MEN1KMT2ATDP1 | |
| SCHEMBL24124153 | 0.71 | — | — | |
| SCHEMBL21246749 | 0.69 | HRH4 (0.45) | GAAKMT2A | |
| SCHEMBL21246746 | 0.69 | HRH4 (0.41) | KMT2A | |
| SCHEMBL27518897 | 0.68 | AGBL2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078193-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-08-03 | — | — | US | disclosed |
| CN-112321497-A | Preparation method of 4-aminopyridine compound | 南京正荣医药化学有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-110483484-A | Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug | JANSSEN SCIENCES IRELAND UC | 2019-11-22 | — | — | CN | disclosed |
| CN-105980378-B | Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B | 爱尔兰詹森科学公司 | 2019-09-27 | — | — | CN | disclosed |
| EP-3102572-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-10-24 | — | — | EP | disclosed |
| EP-3102572-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-12-14 | — | — | EP | disclosed |
| US-20160347741-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC | 2016-12-01 | — | — | US | disclosed |
| CN-105980378-A | Sulfamoyl pyrrole amide derivative and application thereof as medicine for treating hepatitis B | 爱尔兰詹森科学公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2015118057-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-13 | — | — | WO | disclosed |
| US-6960568-B2 | Nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040116362-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | ADAR, DCTD, ADA | GAA 662/4885MEN1 3193/4885KMT2A 1571/4885 |
| US-11078193-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, SRR, RRP12 | GAA 3653/4885MEN1 3042/4885KMT2A 908/4885 |
| US-20160347741-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, SRR, RRP12 | GAA 3653/4885MEN1 3042/4885KMT2A 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.